Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Akcea Therapeutics Jumped 30% Today

By Brian Orelli, PhD - Oct 7, 2019 at 12:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A licensing deal gives investors confidence in a turnaround.

What happened

Shares of Akcea Therapeutics (AKCA) are up 30% at 12:25 p.m. EDT after the biotech announced a licensing deal for its drug candidate, AKCEA-ANGPTL3-Lrx, with Pfizer (PFE -3.32%). Ionis Pharmaceuticals (IONS -5.79%), which is still a majority owner of its spin-off Akcea, saw its shares jump 4%.

So what

AKCEA-ANGPTL3-LRx uses Ionis' antisense technology to knock down expression of a protein called angiopoietin-like 3 (ANGPTL3), which is responsible for regulating cholesterol, glucose, and energy metabolism. The drug is currently in a phase 2 study of patients with type 2 diabetes, hypertriglyceridemia (high triglyceride levels) and nonalcoholic fatty liver disease, which should read out in the first half of next year.

Akcea will get $250 million upfront from Pfizer. Ionis is due half of that payment, but Akcea will pay for it with $125 million in its stock. Akcea and Ionis are eligible to split development, regulatory, and sales milestone payments of up to $1.3 billion from Pfizer. They'll also split tiered, double-digit royalties on annual worldwide net sales of the drug if it's approved.

Pfizer will take over development after the current phase 2 study completes. Before Pfizer files for regulatory approval, Akcea can exercise its option to participate in the marketing of the drug with Pfizer in the U.S. and certain additional markets.

Arms in business suits shaking hands

Image source: Getty Images.

Now what

Part of today's large move in Akcea's stock price has to do with a recent decline following the departures of its CEO, president, and chief operating officer last month. The press release didn't say explicitly, but it seems likely the board was unhappy with the launches of Waylivra and Tegsedi.

Today's transaction is a sign that new management can get deals done -- although presumably talks were started by the previous management -- but interim CEO Damien McDevitt still needs to show he can increase sales of Waylivra and Tegsedi.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Ionis Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$48.29 (-3.32%) $-1.66
Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$43.44 (-5.79%) $-2.67
Akcea Therapeutics, Inc. Stock Quote
Akcea Therapeutics, Inc.
AKCA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.